Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.92M | 2.86M | 3.27M | 3.10M | 2.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.24M | 14.09M | 13.29M | 11.91M | 8.93M |
| Operating Income | -12.24M | -14.09M | -13.29M | -11.91M | -8.93M |
| Income Before Tax | -11.40M | -13.27M | -12.36M | -10.91M | -7.80M |
| Income Tax Expenses | 16.00K | -31.00K | -8.00K | -8.00K | 18.00K |
| Earnings from Continuing Operations | -11.42M | -13.24M | -12.35M | -10.90M | -7.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.42M | -13.24M | -12.35M | -10.90M | -7.82M |
| EBIT | -12.24M | -14.09M | -13.29M | -11.91M | -8.93M |
| EBITDA | -12.21M | -14.05M | -13.25M | -11.87M | -8.90M |
| EPS Basic | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.08 | -0.07 | -0.05 |
| EPS Diluted | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.08 | -0.07 | -0.05 |
| Average Basic Shares Outstanding | 106.01M | 101.28M | 101.04M | 99.52M | 99.49M |
| Average Diluted Shares Outstanding | 106.01M | 101.28M | 101.04M | 99.52M | 99.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |